Rocket Pharmaceuticals, Inc. (RCKT) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Company Overview - Rocket Pharma is a late-stage gene therapy company focused on rare cardiac diseases and has a hematology and immunology platform [2] - The company is integrated across the entire process from discovery to development and commercialization [2] Financial Position - As of the end of last year, Rocket Pharma had $189 million in cash, which is projected to sustain operations into Q2 2027 [2] Key Milestones - The company anticipates a potential approval for KRESLADI, its LAD-1 ex vivo lenti program, with a PDUFA date set for March 28, 2026 [3] - LAD-1 is a primary immunodeficiency that severely affects children, leading to high mortality rates in early childhood [4]